Boostrix Approved for Adults ≥65 Years

BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) by GlaxoSmithKline
BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) by GlaxoSmithKline
GlaxoSmithKline announced that the FDA has approved Boostrix (tetanus and reduced diphtheria toxoid, acellular pertussis vaccine, adsorbed [Tdap]) for use in adults ≥65 years for active booster immunization against tetanus, diphtheria and pertussis. Boostrix is already indicated for use in patients ≥10 years of age.

For more information call (888) 825-5249 or visit www.gsk.com.